T. Rowe Price Associates’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

T. Rowe Price Associates’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-27,677	Closed	-$266K	–	3105
2024 Q4	$266K	Buy	27,677 +5,491	+25%	+$28.6K	﹤0.01%	2563
2024 Q3	$64K	Buy	22,186 +715	+3%	+$2.21K	﹤0.01%	2898
2024 Q2	$63K	Buy	21,471 +2,654	+14%	+$7.26K	﹤0.01%	2829
2024 Q1	$61K	Buy	18,817 +2,280	+14%	+$7.6K	﹤0.01%	2852
2023 Q4	$56K	Buy	16,537 +2,706	+20%	+$6.97K	﹤0.01%	2795
2023 Q3	$33K	Hold	13,831	–	–	﹤0.01%	2825
2023 Q2	$25K	Buy	+13,831	New	+$35.3K	﹤0.01%	2858

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

T. Rowe Price Associates's PSTX Position: Q1 2025 in Review

T. Rowe Price Associates sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 27,677 shares — an estimated $266K sold.

T. Rowe Price Associates first reported a position in PSTX in Q2 2023 and held it in 7 quarters. The position peaked at $266K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

T. Rowe Price Associates reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
T. Rowe Price Associates sold 27,677 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $266K.
T. Rowe Price Associates first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2023 and held it in 7 quarters.
T. Rowe Price Associates's Poseida Therapeutics, Inc. Common Stock position peaked at $266K in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on T. Rowe Price Associates's 13F filing for Q1 2025, filed 14 May 2025.